SG11202113132YA - Anti-gal9 immune-inhibiting binding molecules - Google Patents

Anti-gal9 immune-inhibiting binding molecules

Info

Publication number
SG11202113132YA
SG11202113132YA SG11202113132YA SG11202113132YA SG11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA
Authority
SG
Singapore
Prior art keywords
antigen binding
binding molecule
galy
cdrs
gal9
Prior art date
Application number
SG11202113132YA
Other languages
English (en)
Inventor
Michelle Wykes
Dileep K Pulukkunat
Original Assignee
Council Queensland Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Queensland Inst Medical Res filed Critical Council Queensland Inst Medical Res
Publication of SG11202113132YA publication Critical patent/SG11202113132YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202113132YA 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules SG11202113132YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855590P 2019-05-31 2019-05-31
US201962900105P 2019-09-13 2019-09-13
PCT/AU2020/050546 WO2020237320A1 (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Publications (1)

Publication Number Publication Date
SG11202113132YA true SG11202113132YA (en) 2021-12-30

Family

ID=73552467

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113132YA SG11202113132YA (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Country Status (9)

Country Link
US (1) US20220227873A1 (cg-RX-API-DMAC7.html)
EP (1) EP3976102A4 (cg-RX-API-DMAC7.html)
JP (2) JP7797203B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220030934A (cg-RX-API-DMAC7.html)
AU (1) AU2020285369A1 (cg-RX-API-DMAC7.html)
CA (1) CA3141640A1 (cg-RX-API-DMAC7.html)
IL (1) IL288561A (cg-RX-API-DMAC7.html)
SG (1) SG11202113132YA (cg-RX-API-DMAC7.html)
WO (1) WO2020237320A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202113222PA (en) * 2019-05-31 2021-12-30 Council Queensland Inst Medical Res Activating anti-gal9 binding molecules
TW202400639A (zh) * 2022-05-13 2024-01-01 美商艾克塞里克斯公司 5t4結合劑及其用途
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途
KR20250159082A (ko) * 2023-01-27 2025-11-07 엑셀리시스, 인코포레이티드 Nkg2a 결합제 및 이의 용도
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
CA2954678A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy

Also Published As

Publication number Publication date
JP7797203B2 (ja) 2026-01-13
EP3976102A4 (en) 2023-07-12
CA3141640A1 (en) 2020-12-03
JP2022534433A (ja) 2022-07-29
US20220227873A1 (en) 2022-07-21
WO2020237320A1 (en) 2020-12-03
IL288561A (en) 2022-02-01
AU2020285369A1 (en) 2021-12-23
JP2025146842A (ja) 2025-10-03
CN114025797A (zh) 2022-02-08
KR20220030934A (ko) 2022-03-11
EP3976102A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
US11851502B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
TWI797065B (zh) 對人類cd19具專一性之抗體藥劑及其用途
CA2965745C (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
TWI585102B (zh) 拮抗cd40l之抗體多肽
US12006367B2 (en) CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
JP2020529832A (ja) IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
JP7797203B2 (ja) 抗gal9免疫阻害性結合分子
KR20220147631A (ko) 면역 반응을 조절하기 위한 물질 및 방법
EP4228693A1 (en) Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
JP2023520636A (ja) T細胞二重特異性結合タンパク質
EP4499683A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
JP2022538461A (ja) Cd38およびcd3に結合するヘテロ二量体抗体
US20220235135A1 (en) Activating anti-gal9 binding molecules
WO2021116277A1 (en) New antibody blocking human fcgriiia and fcgriiib
EP4709763A1 (en) Agents that bind to cd16a and uses thereof
HK1227904A (en) Production of t cell retargeting hetero-dimeric immunoglobulins
HK1227904A1 (en) Production of t cell retargeting hetero-dimeric immunoglobulins